Robert McQuade, Ph.D.
Bob is EVP and Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and President of the McQuade Center for Strategic Research and Development (MSRD).
Bob has more than 35 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness and kidney diseases. At OPDC, Bob is responsible for coordinating the development strategy for Otsuka’s compounds across their life cycles. Over the past 15 years, Dr. McQuade has been instrumental in the development and approval of Abilify Maintena® (depot formulation of aripiprazole), Rexulti® (brexpiprazole and Samsca®/Jynarque® (tolvaptan) at OPDC. Earlier this year he established the MSRD, a limited liability company that has been funded by the Otsuka U.S. pharmaceutical business, which has the purpose to search for, identify and fund innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products.
Bob began his career as a research scientist in central nervous system (CNS) drug discovery at Schering-Plough. Subsequently, Bob held leadership positions at Bristol-Myers Squibb (BMS) in Medical Affairs. The highlight of Bob’s tenure at BMS was the instrumental role he played in creating the BMS-Otsuka alliance and in shepherding Abilify® (aripiprazole) through clinical development and regulatory approval for a number of indications, including schizophrenia, bipolar disorder and adjunctive treatment of major depressive disorder.